Italy Diabetes Devices Market Analysis

Italy Diabetes Devices Healthcare Market Executive Analysis

The Italy Diabetes Devices Market is at around $546 Mn in 2022 and is projected to reach $916 Mn in 2030, exhibiting a CAGR of 6.70% during the forecast period. The Italian Finance Act sets a recurring overall resource amount for the National Health System (NHS) expenditures that the State funds. The National Health Fund (NHF) will receive $2.11 billion more in financing over the course of the 2022 Finance Act, increasing it from $128.73 billion to $130.84 billion in 2022, $132.95 billion in 2023, and $135.06 billion in 2024. The budget allocated for the purchase of novel medications will increase by an extra $105.52 million, $211.04 million, and $316.56 million in 2022, 2023, and 2024, respectively.

Around 3.8 million Italians, or 7.5% of the adult population aged 20 to 79, had diabetes. Compared to earlier projections, which put the prevalence at 5.5% in 2017, this is a significant rise. Italy had a type 1 diabetes incidence of roughly 16.4 per 100,000 people, compared to a type 2 diabetes incidence of roughly 7.6 per 100,000 people. The research also discovered that type 2 diabetes incidence rose with age and that type 1 diabetes prevalence was higher in men than in women. Over 90,000 pregnancies in Italy resulted in a 12% incidence of gestational diabetes. Future type 2 diabetes in women with prenatal diabetes was more probable to occur.

In Italy, people with diabetes use diabetes devices to keep healthy glucose levels and avoid complications from the disease. Diabetes management and monitoring instruments are medical devices. These tools are used to administer insulin, check blood glucose levels, and monitor glucose levels over time. Blood glucose levels are measured in real-time by diabetes instruments like blood glucose meters. People with diabetes need to know this information in order to make smart choices about their food, exercise routine, and medication. People with diabetes use insulin syringes and insulin pumps as insulin delivery systems. With the aid of these gadgets, diabetics can better control their blood sugar levels and lower their risk of problems. Diabetes management is made easier for those with the illness thanks to diabetes devices, which can also enhance their quality of life. Diabetes devices assist in lowering the chance of complications related to diabetes by monitoring glucose levels and delivering insulin as required. Diabetes devices are more available and cheaper for people with diabetes in Italy thanks to the national health insurance system's frequent coverage of them.

Market Dynamics

Market Growth Drivers

In Italy, the number of cases of diabetes has been gradually rising in recent years. The market for diabetes devices and associated goods will increase as a result of this trend, which is predicted to continue. Demand in the market is anticipated to rise as a result of the creation of novel and enhanced diabetes gadgets. Market share will probably rise for producers who make investments in R&D to produce cutting-edge and potent products. As older people are more likely to acquire diabetes and need management tools, the ageing population in Italy is predicted to increase the demand for diabetes devices. The Italian government has started programs to enhance diabetes management and lower the expenses of treating the condition. These initiatives might be advantageous to manufacturers who can offer affordable options. Demand for these products is anticipated to rise as more people become conscious of the value of managing their diabetes and as diabetes devices become more readily available. Manufacturers who successfully promote their goods to customers may see an increase in sales.

Market Restraints

Italy's market for diabetes devices is extremely competitive, with many businesses selling comparable goods. Manufacturers who are unable to distinguish their goods may find it difficult to expand their market position. Italy's tightly regulated diabetes device industry presents challenges for producers. Businesses that can't comply with regulations may have trouble getting their goods approved. Despite the fact that there is a rise in diabetes knowledge, some patients might not be aware of the advantages of diabetes devices or how to use them. Gaining market share may be difficult for manufacturers who are unable to successfully educate consumers.

Competitive Landscape

Key Players

• Ormesa S.R.L. (IT)
• Angelantoni Life Science (IT)
• Johnson & Johnson
• Medtronic
• Roche
• Dexcom
• Ascensia Diabetes Care

Recent Notable Deals

September 2021: Abbott declared in September 2021 that the Italian National Health Service had approved payment for its FreeStyle Libre continuous glucose monitoring device. (SSN). Given that it increased access to its product for diabetic patients, the approval was viewed as a major victory for Abbott in the Italian market.

Healthcare Policies and Regulatory Landscape

In Italy, the National Health Service (SSN) offers comprehensive coverage for medical services, including diabetes treatment. The SSN pays for a lot of diabetes devices, but in order for makers to be eligible for reimbursement, they must adhere to rigid rules. The regulatory body in charge of authorizing, governing, and overseeing diabetes devices and healthcare products in Italy is called Agenzia Italiana del Farmaco (AIFA). Before putting their products on the Italian market, manufacturers must get AIFA's permission. To market their diabetes devices in Italy, manufacturers need to have CE marking authorization in addition to AIFA approval. This accreditation certifies that the item complies with all safety, health, and environmental protection standards set forth by the European Union (EU). Italian clinical trials for diabetes devices may be necessary for clearance by manufacturers. Both the local ethics committee and EU rules must be met for these trials to proceed. Diabetes device reimbursement procedures in Italy can differ by area, and producers must negotiate complicated rules to make sure their products are covered by insurance. They must also adhere to the stringent pricing guidelines established by AIFA.